Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (56)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Davis, W.
Right arrow Articles by Phillips, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, W.
Right arrow Articles by Phillips, D. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol 19, 861-866, Copyright © 1998 by Oxford University Press

ARTICLES

The metabolic activation of tamoxifen and alpha-hydroxytamoxifen to DNA- binding species in rat hepatocytes proceeds via sulphation

W Davis, S Venitt and DH Phillips
Section of Molecular Carcinogenesis, Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, UK. warren@icr.ac.uk

The biotransformation pathway of tamoxifen and alpha-hydroxytamoxifen to DNA-binding species was investigated in rat hepatocytes in vitro. Rat hepatocytes were isolated by in situ collagenase perfusion and then maintained in sulphate-free Dulbecco's modified Eagle's medium. Magnesium sulphate was added to the medium to give concentrations of 0- 10 microM, prior to treatment for 18 h with solvent vehicle (DMSO), tamoxifen (10 microM), alpha-hydroxytamoxifen (1 microM) or benzo[a]pyrene (BaP) (10 and 50 microM). DNA was isolated and analysed by 32P-post-labelling. For tamoxifen and alpha-hydroxytamoxifen, the level of DNA adduct formation was directly proportional to the concentration of sulphate in the medium. Between 0 and 10 microM MgSO4, the DNA adduct level increased 10-fold with both compounds. Rat hepatocytes were also maintained in normal Dulbecco's modified Eagle's medium and pretreated with dehydroisoandrosterone-3-sulphate (DHEAS, a sulphotransferase inhibitor) at concentrations ranging from 0-1 mM, prior to treatment with solvent vehicle (DMSO), tamoxifen (10 microM), alpha-hydroxytamoxifen (1 microM) or BaP (50 microM). For tamoxifen and alpha-hydroxytamoxifen the level of DNA adducts was reduced to approximately one-fifth by the addition of DHEAS (0.1 mM). BaP-DNA adduct formation, which proceeds by a pathway that does not require sulphation, was not significantly affected by sulphate concentration or by addition of DHEAS, which demonstrates that the general metabolic capacity and viability of the hepatocytes were not compromised. It is concluded that the activation of tamoxifen in rat liver cells to DNA binding products proceeds predominantly through hydroxylation followed by sulphate ester formation at the alpha-position of the ethyl side chain.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
K. Brown
Is tamoxifen a genotoxic carcinogen in women?
Mutagenesis, September 1, 2009; 24(5): 391 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
E. Liapis, K. I.E. McLuckie, P. D. Lewis, P. B. Farmer, and K. Brown
Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots
Nucleic Acids Res., October 1, 2008; 36(18): 5933 - 5945.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Brown, E. M. Tompkins, D. J. Boocock, E. A. Martin, P. B. Farmer, K. W. Turteltaub, E. Ubick, D. Hemingway, E. Horner-Glister, and I. N.H. White
Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose
Cancer Res., July 15, 2007; 67(14): 6995 - 7002.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Y. Kim, Y. R. S. Laxmi, N. Suzuki, K. Ogura, T. Watabe, M. W. Duffel, and S. Shibutani
FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF {alpha}-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS
Drug Metab. Dispos., November 1, 2005; 33(11): 1673 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt
Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment
Mutagenesis, July 1, 2005; 20(4): 297 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. I. Apak and M. W. Duffel
INTERACTIONS OF THE STEREOISOMERS OF {alpha}-HYDROXYTAMOXIFEN WITH HUMAN HYDROXYSTEROID SULFOTRANSFERASE SULT2A1 AND RAT HYDROXYSTEROID SULFOTRANSFERASE STA
Drug Metab. Dispos., December 1, 2004; 32(12): 1501 - 1508.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. J. Boocock, K. Brown, A. H. Gibbs, E. Sanchez, K. W. Turteltaub, and I. N.H. White
Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA
Carcinogenesis, November 1, 2002; 23(11): 1897 - 1902.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Chen, G. Gamboa da Costa, M.M. Marques, S. D. Shelton, F. A. Beland, and M. G. Manjanatha
Mutations induced by {alpha}-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats
Carcinogenesis, October 1, 2002; 23(10): 1751 - 1758.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland
DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives
Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. H. Phillips
Understanding the genotoxicity of tamoxifen?
Carcinogenesis, June 1, 2001; 22(6): 839 - 849.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
I. N.H. White, P. Carthew, R. Davies, J. Styles, K. Brown, J. E. Brown, L. L. Smith, and E. A. Martin
Short-term dosing of {{alpha}}-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats
Carcinogenesis, April 1, 2001; 22(4): 553 - 557.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. J. Boocock, J. L. Maggs, K. Brown, I. N.H. White, and B.K. Park
Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of {alpha}-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts
Carcinogenesis, October 1, 2000; 21(10): 1851 - 1858.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Umemoto, Y. Monden, M. Suwa, Y. Kanno, M. Suzuki, C.-X. Lin, Y. Ueyama, Md.A. Momen, A. Ravindernath, S. Shibutani, et al.
Identification of hepatic tamoxifen-DNA adducts in mice: {alpha}-(N2-deoxyguanosinyl)tamoxifen and {alpha}-(N2-deoxyguanosinyl)tamoxifen N-oxide
Carcinogenesis, September 1, 2000; 21(9): 1737 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Shibutani, A. Ravindernath, N. Suzuki, I. Terashima, S. M. Sugarman, A. P. Grollman, and M. L. Pearl
Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen
Carcinogenesis, August 1, 2000; 21(8): 1461 - 1467.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Davis, A. Hewer, K. M. Rajkowski, W. Meinl, H. Glatt, and D. H. Phillips
Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction
Cancer Res., June 1, 2000; 60(11): 2887 - 2891.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Bartsch, D. H. Phillips, J. Nair, A. Hewer, G. Meyberg-Solomeyer, and E.-M. Grischke
Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients
Carcinogenesis, April 1, 2000; 21(4): 845 - 847.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. H. Phillips, A. Hewer, M. N. Horton, K. J. Cole, P. L. Carmichael, W. Davis, and M. R. Osborne
N-Demethylation accompanies {alpha}-hydroxylation in the metabolic activation of tamoxifen in rat liver cells
Carcinogenesis, October 1, 1999; 20(10): 2003 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Brown, R. T. Heydon, R. Jukes, I. N.H. White, and E. A. Martin
Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen
Carcinogenesis, October 1, 1999; 20(10): 2011 - 2016.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
I. N.H. White
The tamoxifen dilemma
Carcinogenesis, July 1, 1999; 20(7): 1153 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. R. Osborne, A. Hewer, W. Davis, A. J. Strain, A. Keogh, I. R. Hardcastle, and D. H. Phillips
Idoxifene derivatives are less reactive to DNA than tamoxifen derivatives, both chemically and in human and rat liver cells
Carcinogenesis, February 1, 1999; 20(2): 293 - 297.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Rajaniemi, I. Rasanen, P. Koivisto, K. Peltonen, and K. Hemminki
Identification of the major tamoxifen–DNA adducts in rat liver by mass spectroscopy
Carcinogenesis, February 1, 1999; 20(2): 305 - 309.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
P. L. Carmichael, S. Sardar, N. Crooks, P. Neven, I. Van Hoof, A. Ugwumadu, T. Bourne, E. Tomas, P. Hellberg, A. J. Hewer, et al.
Lack of evidence from HPLC 32P-post-labelling for tamoxifen–DNA adducts in the human endometrium
Carcinogenesis, February 1, 1999; 20(2): 339 - 342.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.